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Abstract
Background: Autoantibodies directed against the 160 kDa endosome protein early endosome
antigen 1 (EEA1) are seen in patients with neurological diseases. To determine if antibodies to EEA1
have a neuropathological effect, mice from three major histocompatability haplotype backgrounds
(H2q, H2b and H2d) were immunized with EEA1 (amino acids 82–1411) that was previously shown
to contain the target EEA1 epitopes. The mice were then subjected to five neuro-behavioural tests:
grid walking, forelimb strength, open field, reaching and rotarod.
Results: The immunized SWR/J mice with sustained anti-EEA1 antibodies had significantly reduced
forelimb strength than the control non-immune mice of the same strain, and BALB/CJ immune mice
demonstrated significantly more forelimb errors on the grid walk test than the control group.
Conclusions: Antibodies to recombinant EEA1 in mice may mediate neurological deficits that are
consistent with clinical features of some humans that spontaneously develop anti-EEA1
autoantibodies.
Background
Autoimmune neurological diseases occur after alterations
of immunological tolerance to certain components of the
nervous system. The factors that cause the breakdown of
tolerance and the subsequent autoantigen-specific activa-
tion of self-reactive B and T lymphocytes are not well
understood. A small number of autoimmune neurologi-
cal diseases, such as myasthenia gravis, are well character-
ized whereas many others are still the subject of intense
research [1-3]. The influence of genetic [4] and hormonal
[5] factors on autoimmunity are among the best under-
stood co-morbid variables in disease expression.
Autoantibodies to early endosome antigen 1 (EEA1) were
reported in the sera of the patients with neurological dis-
orders [6,7], but the pathological significance of EEA1
antibodies is not known. EEA1 is a peripheral endosomal
protein expressed in a variety of tissues, including nervous
tissues [6,8-10]. Since early endosomes are key functional
components of both pre-synaptic and post-synaptic neu-
rons [11,12], the association of EEA1 autoantibodies with
neurological diseases suggests a number of interesting
clinical and neurobiology studies.
In order to investigate if EEA1 autoantibodies may under-
lie the clinical expression of disease, studies in vivo were
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conducted by immunizing thirty-six female mice with
EEA1 recombinant protein, followed by the evaluation of
the neurological and behavioral skills two months after
immunization. The observations in this study indicated
that mice bearing anti-EEA1 antibodies developed
impaired neurological and behavioral skills.
Results
Generation of anti-EEA1 autoantibodies in mice
All mice from the experimental group that were immu-
nized with the recombinant EEA1 protein but not those
that received adjuvant alone, developed autoantibodies
that displayed an endosomal cytoplasmic staining pattern
that co-localized with index human serum (Figure 1).
Some C57BL/6J mice anti-EEA1 sera displayed weak
nuclear staining in addition to the vesicular cytoplasmic
staining pattern.
The antibody response was followed and quantitated
using the addressable laser bead immunoassay (Table 1).
All pre-immune mouse sera had median fluorescence
units (MFU) of <700. Eight weeks after the initial immu-
nization, the MFU increased and was sustained at >4500
in SWR/J, >4300 in C%&BL/6J, and >7500 in BALB/CJ
mice.
Indirect immunofluorescence of anti-EEA1 sera induced in SWR/J (top row), C57BL/6J (middle row) and BALB/CJ (bottom  row) mice by immunization with purified recombinant EEA1 Figure 1
Indirect immunofluorescence of anti-EEA1 sera induced in SWR/J (top row), C57BL/6J (middle row) and BALB/CJ (bottom 
row) mice by immunization with purified recombinant EEA1. The immunized mice produced a cytoplasmic vesicular staining 
pattern (panels a: red) that co-localized with the human prototype anti-EEA1 serum (panels b: green) on HEp-2 cells. The red 
(a) and green (b) merged panels are shown in panels c. Original magnification 400 ×.BMC Neuroscience 2004, 5 http://www.biomedcentral.com/1471-2202/5/2
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Grid walking and forelimb strength
Eight weeks after immunization, the mice were subjected
to the five neurological and behavioural tests. The average
number of forelimb and hind limb errors that were
recorded while each mouse traversed the grid (Figure 2).
The analyses showed that there were no statistically signif-
icant differences between immune and control mice on
forelimb or hind limb errors for SWR/J (t = -1.3, p = .21, t
= 1.14, p = .28), or C57BL/6J (t = .54, p = .60, t = -1.6, p =
.14) mice. However, there was a significant difference
between immune and non-immune BALB/CJ mice on
forelimb errors (t = 2.24, p = .049), but not on hind limb
errors (t= p = .18).
When forelimb strength was analyzed separately for each
strain, a significant difference was observed between the
immune and non-immune groups of SWR/J (F(1,10) =
6.347, p = .03) mice (Figure 3). No significant differences
were observed between the study groups of C57BL/6J or
BALB/CJ mice (F(1,10) = 3.685, p = .08, F(1,10) = .702, p
= .42). In summary, the experimental group of strain
SWR/J was significantly weaker than the control group.
The difference in strength scores for the C57BL/6J mice
bearing anti-EEA1 antibodies compared with the non-
immune control group approached statistical signifi-
cance. This suggested a trend toward greater weakness in
the immunized experimental group in comparison to the
non-immune control group.
Open field, reaching and rotatrod tests
The performance of the mice in the open field, reaching
and rotarod tests did not reveal any statistically significant
differences between the non-immune control and immu-
nized experimental groups (Figures 4,5,6,7). The total dis-
tance traveled during 20 min of observation in the open
field for all three mouse strains is shown in Figure 4. A
repeated measures analysis of variance (ANOVA) showed
that there was no statistically significant difference
between SWR/J control and experimental groups (F(1,40)
= .051, p = .83) (Figure 4, top panel). Both groups did
travel progressively less over bins (F(4,40) = 82.12, p <
.0001) and changed similarly over the bins (F(4,40) =
1.163, p = .34). The C57BL/6J non-immune control group
tended to be more active overall than the immunized
group (Figure 4, middle panel), however, a repeated
measure ANOVA showed that this difference was not sta-
tistically significant (F(1,40) = 1.05, p = .33). Both groups
did travel progressively less over the bins (F(4,40) = 11.39,
p < .0001) and there was a trend for a significant interac-
tion between bin and distance traveled but this difference
was not statistically significant (F(4,40) = 2.17, p = 0.09).
Table 1: Measurement of antibodies to early endosome antigen 1 (EEA1) by an addressable laser bead immunoassaya
Mouse Strain Pre-immune MFU (range) Eight Weeks After Immunization MFU 
(range)
SWR/J 235 (197–254) 4545 (989–9677)
C57BL/6J 209 (226–373) 4303 (675–5396)
BALB/CJ 329 (221–666) 7854 (3842–10660)
a results of assay shown as the mean of median fluorescence units (MFU)
Forelimb (top panel) and hind limb errors (bottom panel) in  SWR/J (1), C57BL/6J (2) and BALB/CJ (3) mice while travers- ing a grid Figure 2
Forelimb (top panel) and hind limb errors (bottom panel) in 
SWR/J (1), C57BL/6J (2) and BALB/CJ (3) mice while travers-
ing a grid. Immunized mice bearing anti-EEA1 antibodies (1a, 
2a, 3a respectively) were compared to the same strain of 
non-immune control mice (1b, 2b, 3b). This test revealed 
that the BALB/CJ mice bearing anti-EEA1 antibodies made 
significantly more forelimb errors than the control non-
immune group.
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A repeated measures ANOVA showed that BALB/CJ con-
trol group traveled less distance than the experimental
group (F(1,40) = 11.38, p = .007) (Figure 4, bottom
panel). Both groups did travel progressively less over the
5 bins (F(4,40) = 10.38, p < .0001) and the groups
changed similarly over the bins (F(4,40) = .203, p = .23).
The total number of rears (supported and unsupported)
and the number of unsupported rears for each mice strain
is summarized in Figure 5. A one-way ANOVA shows that
SWR/J control and experimental groups do not differ in
the number of rears (F(1,10) = .257, p = .62), nor in the
number of unsupported rears (F(1,10) = 1.905, p = .198).
Similar observations were recorded for the two BALB/CJ
study groups: rears (F(1,10) = .907, p = .36); unsupported
rears (F(1,10) = 1.348, p = .27). By comparison, the differ-
ences of rears (F(1,10) = 4.514, p = .0596) and unsup-
ported rears (F(1,10) = 4.233, p = .0667) between C57BL/
6J non-immune control and immune groups did
approach but did not achieve statistical significance.
Over the five days of conditioning, the mice learned to
retrieve food pellets from the tray by reaching with their
forepaw through the vertical bars. On the sixth day, the
animals were individually placed in the reaching box and
reaching was videotaped for 5 consecutive minutes, begin-
ning with the first reaching attempt. Figure 6 shows the
total number of attempted reaches and the percentage of
hits (number of successful reaches over the total number
of attempted reaches). One way ANOVA analysis of the
data for each strain showed that there were no significant
differences between the immune and non-immune
groups of each mouse strain (F(1,10) = 1.079, p = .32,
F(1,10) = 2.026, p = .188, F(1,10) = .331, p = .58 for SWR/
J, C57BL/6J, and BALB/CJ strains respectively).
After all mice were trained to walk on a rotating drum (6
sessions over 2 days), the rotational speed of the rotarod
at time when the mouse fell from the drum was recorded
(Figure 7). Repeated measure ANOVA shows that there
were no statistically significant differences between the
The average forelimb strength was tested in the immunized  group (a) and non-immune control group (b) of SWR/J (1),  C57BL/6J (2) and BALB/CJ (3) mice Figure 3
The average forelimb strength was tested in the immunized 
group (a) and non-immune control group (b) of SWR/J (1), 
C57BL/6J (2) and BALB/CJ (3) mice. The immunized SWR/J 
mice were significantly weaker than the control non-immune 
group, whereas the difference in strength scores for the 
C57BL/6J mice bearing anti-EEA1 antibodies did not achieve 
statistical significance when compared to the non-immune 
control group.
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The distance travelled in the open field test was measured in  the immunized mice (a) and the non-immune control group  (b) Figure 4
The distance travelled in the open field test was measured in 
the immunized mice (a) and the non-immune control group 
(b). Statistically significant differences were not observed in 
these groups.
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study groups of any of the mouse strains (F(1,10) = 2.85,
p = .12, F(1,10) = 0.07, p = .80, F(1,10) = .85, p = .38).
SWR/J mice did show a significant improvement on sub-
sequent trials (F(1,5) = 5.5, p = .0004), whereas C57BL/6J
and BALB/CJ mice did not show significant improvement
(F(1,5) = 1.5, p = 0.21, F(1,5) = 0.81, p = .55).
In this study we used mice immunized with EEA1 as an
approach to determine if anti-EEA1 autoantibodies were
associated with functional neurological deficits in vivo.
The experimental approach to neurological and func-
tional behavior abnormalities that we used in these stud-
ies are detailed and validated by others http://
www.neurod.com/behavior_w.htm[13]. We observed
that mice immunized with an EEA1 recombinant protein
displayed a statistically significant impaired performance
on two out of five of these tests. Significantly reduced fore-
limb strength was recorded in SWR/J mice that had sus-
tained anti-EEA1 antibodies when compared to the
control non-immune mice. The immunized BALB/CJ
mice demonstrated significantly more forelimb errors on
the grid walk test than did the control non-immune mice.
In addition, C57BL/6J mice had lower forelimb strength
scores that approached statistical significance, indicating
that the experimental group tended to be weaker than the
control group. Of interest, it was observed that the non-
immune control group showed a tendency to be less
active and to show less rearing than the experimental
group. This suggested that mice bearing anti-EEA1 may
have expressed other neurological features, such as hyper-
activity, that were not formally or objectively evaluated in
this study.
It is important to note that the data collected for the
behavioral studies reported here were expressed as mean
values for each group of mice and this approach may
obscure profound abnormalities in a single animal. For
example, if only 50% of animals immunized with anti-
EEA1 antibodies developed the neurological features of
disease symptoms, the mean performance score on each
test would be less obvious than if individual values would
be compared.
The tests of forelimb strength and grid walk were used to
evaluate deficits in descending motor control and global
muscular tone. Although it is possible that antibodies to
EEA1 were responsible for these neurological deficits, it is
appreciated that the co-morbid variables that combine to
express a disease state might not be the simple result of a
The number of rears during 20 min in the open field was  recorded in the immunized group (a) and non-immune con- trol (b) mice Figure 5
The number of rears during 20 min in the open field was 
recorded in the immunized group (a) and non-immune con-
trol (b) mice. The differences of rears (F(1,10) = 4.514, p = 
.0596) and unsupported rears (F(1,10) = 4.233, p = .0667) 
between C57BL/6J non-immune control and immunized 
groups approached, but did not achieve, statistical signifi-
cance. Statistically significant differences were not observed 
in the other genetic strains of mice.
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The percent of hits achieved in reaching for sweet pellets  was recorded in SWR/J, C57BL/6J and BALB/CJ immunized  mice (1a, 2a and 3a respectively) and were compared to the  same strain of non-immune control mice (1b, 2b, 3b) Figure 6
The percent of hits achieved in reaching for sweet pellets 
was recorded in SWR/J, C57BL/6J and BALB/CJ immunized 
mice (1a, 2a and 3a respectively) and were compared to the 
same strain of non-immune control mice (1b, 2b, 3b). Statisti-
cally significant differences were not observed in these 
groups of mice.
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immunization with an autoantigen. Genetic, environ-
mental and hormonal influences are known to operate in
concert to result in pathogenesis and expression of disease
features [2,14,15]. For example, experimental autoim-
mune encephalitis, which shows pathological similarities
to human multiple sclerosis, can be induced in SJL mice
by immunization with myelin basic protein (MBP) [16],
whereas BALB/C mice are resistant to development of the
disease, despite generation of highly MBP-specific T cell
clones that recognize MBP peptides presented in the com-
plex with MHC class II molecules [17,18]. Of interest, the
different genetic strains of mice used in these studies dem-
onstrated different quantitative responses to the EEA1
immunogen. Notably, BALB/C mice had significantly
higher levels of anti-EEA1 than the other strains and they
exhibited the most remarkable abnormalities in testing
performance.
It is difficult to induce readily detectable pathological
changes in animals comparable to those observed in
human disease. For example, C57BL/6 mice are used as an
animal model of MG, however multiple immunizations
with acetylcholine receptor in complete Freund's adjuvant
were required to induce signs of muscular weakness which
can be detected in only 20%-60% of the animals [19].
This was in contrast to a study that showed pathogenic
autoimmunity to affinity-purified mouse acetylcholine
receptor that was induced without adjuvant in BALB/c
mice [20]. In our mice the abnormalities were observed
after an initial immunization of EEA1 in Freund's adju-
vant followed by a single booster immunization. It is pos-
sible that more profound deficits could be induced by
repeated immunization and the induction of higher levels
of anti-EEA1 responses. In addition, there is the
possibility that the immune response of mice to the
human recombinant antigen may produce antibodies
which differ in specificity and perhaps pathological effect
compared to the human autoantibodies. To address this
issue, epitope mapping of the antibodies produced in
mice and comparison to epitopes bound by naturally
occurring autoantibodies in humans [7] may be
informative.
EEA1 is expressed in a number of tissues [21] and is polar-
ized in hippocampal neurons, epithelial cells and fibrob-
lasts [10]. One of the challenges in understanding the role
of autoantibodies in the pathogenesis of many diseases is
to consider mechanisms other than traditional antibody-
mediated mechanisms (i.e. anti-acetylcholine antibodies
in myasthenia gravis) or immune complex formation (i.e.
anti-DNA antibodies in lupus glomerulonephritis). An
interesting departure from these traditional pathogenetic
mechanisms is the observation that anti-mitochondrial
antibodies (AMA), the serological hallmark of primary
biliary cirrhosis [22], do not directly cause hepatocyte or
bile duct damage but when antigen-presenting dendritic
cells that were pulsed with antigen bound to the cognate
autoantibody there was an increase of cytokines that may
then mediate inflammation and cytotoxicity [23]. This is
an important model and may have relevance to anti-EEA1
because, just like EEA1, the targets of AMA (i.e. pyruvate
dehydrogenase complex) are ubiquitous in many cells
and tissues, but the pathogenic expression of disease is
almost exclusively restricted to the bile ducts.
Conclusions
Studies of mice immunized with recombinant EEA1 pro-
duced high titer antibodies and demonstrated behav-
ioural deficits. Although the behavioral tests provided
The rotational speed of the rotating drum at which mice  SWR/J, C57BL/6J and BALB/CJ mice fell off was recorded for  the immunized experimental (a) and non-immune control (b)  groups Figure 7
The rotational speed of the rotating drum at which mice 
SWR/J, C57BL/6J and BALB/CJ mice fell off was recorded for 
the immunized experimental (a) and non-immune control (b) 
groups. Although SWR/J mice did show a significant improve-
ment on subsequent trials, statistically significant differences 
were not observed in these groups of mice.
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valuable information about the potential pathological
role of EEA1 antibodies, additional studies such as motor
function, nerve conduction studies, T cell proliferative
responses to EEA1 and immunohistological analysis
would help prove that these antibodies autoreactive lym-
phocytes directly or indirectly participate in causing fea-
tures of neurological disease. In addition, passive transfer
of sera could also be conducted before more clear-cut con-
clusions can be drawn.
Methods
Mice strains
Since genetic factors, particularly the major histocompat-
ability (MHC) locus, are known to play a significant role
in expression of autoimmune phenomena, three strains of
female mice (SWR/J, C57BL/6J and BALB/cJ, 12 of each
strain) from different MHC haplotype (H2q, H2b and
H2d) backgrounds were chosen for this study. All mice
were purchased from the Jackson Laboratory (Bar Harbor,
ME) at three weeks of age and housed under standard
housing and feeding regimens in infection controlled
facilities in the Health Sciences Animal Resource Centre at
the University of Calgary. All studies adhered to guide-
lines for animal studies developed by the Canadian Coun-
cil on Animal Care.
Purification of EEA1 recombinant protein
EEA1-cDNA encoding a partial-length EEA1 protein
(EEA182–1411) and characterized in our previous study [6]
was subcloned into a glutatione-S-transferase (GST)-
based vector (pGex6P1) and expressed and purified as a
GST-fusion protein in a protease-deficient AB1899 E. coli
strain using techniques essentially as previously pub-
lished [7].
Immunization
Mice of each strain were divided into two groups (six in
each group). One group (experimental group) received an
intraperitoneal injection of 100 µg of the purified EEA1
recombinant protein in an equal volume of complete Fre-
und's adjuvant. The other group (control) received an
intraperitoneal injection of the GST cleavage buffer com-
bined with an equal volume of complete Freund's adju-
vant. Two weeks later, the mice were boosted with a
subcutaneous injection of either 50 µg of the EEA1 pro-
tein in incomplete Freund's adjuvant, or an equal volume
of GST cleavage buffer in incomplete Freund's adjuvant.
Blood was obtained by retro-orbital collection in capillary
tubes. The appearance and titer of EEA1 antibodies was
monitored for two months by indirect immunofluores-
cence (IIF) of the collected sera on HEp-2 cells (HEp-
2000; Immuno Concepts Inc., Sacramento, CA) using
Alexa 488-conjugated goat anti-mouse IgG (H+L chain)
antibody (Jackson ImmunoResearch Laboratories Inc).
Co-localization of mouse antibodies with an index
human anti-EEA1 antibody was performed using Cy3-
conjugated goat anti-human IgG (H+L chain) (Molecular
Probes, Eugene, OR) or the Alexa 488-conjugated goat
anti-mouse IgG (H+L chain) antibody.
Laser bead immunoassay
Antibodies to EEA1 were detected and quantitated by
using a set of addressable beads bearing laser reactive dyes
(Luminex Corp., Austin, TX) that were covalently coupled
to purified recombinant EEA1 protein as previously
described [7]. To analyze reactivity with EEA1, mouse sera
were diluted in QUANTA Plex™ sample diluent (INOVA,
San Diego, CA) to a final dilution of 1/1000. To each well
40  µl of bead stock (1 part microspheres in blocking
buffer to 40 parts QUANTA Plex sample diluent) and 10
µl of diluted mouse sera were added and incubated for 30
minutes on an orbital shaker. Then fifty µl of phycoeryth-
rin-conjugated goat anti-mouse IgG (Jackson
ImmunoResearch Laboratories) diluted 1/50 was added
to each well and incubated on the orbital shaker for an
additional 30 minutes. The reactivity of the antigen-
coated beads was determined on a Luminex 100™ dual
laser flow cytometer (Luminex Corp.). The reactivity of
antibodies in the assay was expressed as the median fluo-
rescent intensity. A control monoclonal anti-EEA1 (Cyto-
Store - Calgary, AB) and pre-immune mouse sera were
included in the assay. The binding was compared to bind-
ing of an irrelevant monoclonal antibody (golgin97:
CytoStore, Calgary, AB) as a negative control.
Design of the behavioral tests
The motor assessments were conducted at the facilities of
NeuroDetective Inc., Lethbridge, Alberta http://www.neu
rod.com/behavior_w.htm[13]. The experimenters and
behavioral analysts were blinded to mouse strain and
immunized versus non-immunized control status. Thirty-
six female mice (18 control and 18 experimental) were
evaluated for functional motor assessment. The mice
belong to 3 different strains with treated and controls
within each strain (n = 6). The assessments included open
field activity, skilled reaching, grid walking, strength, and
rotarod walking. All behavioral experiments and study
sessions were recorded on videotape. The tests did not
measure behavioural motor deficits.
Open field testing was designed to evaluate hippocampal
and basal ganglia damage, and hindlimb dysfunction.
Each mouse was placed into an open field for 20 minutes
(divided into 4 min bins for analysis). The distance
traveled and the total number of supported (rearing while
bracing against a wall with one or both forelimbs) and
unsupported (rearing without bracing with the forelimbs)
rears was counted. In the open-field test, mice had the
opportunity toexplore a square-shaped arena for a fixed
time. The dependent variablesrecorded were locomotorBMC Neuroscience 2004, 5 http://www.biomedcentral.com/1471-2202/5/2
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activity and the balance between exploration and
agoraphobia.
Reaching  was a test that aimed to evaluate forelimb
motor control and was sensitive to deficits in dopaminer-
gic neurotransmission. The apparatus consisted of a 16 ×
24 cm Plexiglas cage, one side of which consisted of verti-
cal bars that were spaced with gaps between them that
were just large enough for a mouse to reach its forelimb
through to a food tray positioned just outside the bars (5
mm). The food tray contained sweetened pellets. Over the
5 days of conditioning the mice learned to retrieve food
pellets from the tray by reaching their forepaw through
the vertical bars. On the sixth day, individual animals
were placed in the apparatus and reaching was videotaped
for 5 consecutive minutes (beginning with the first reach-
ing attempt). The total number of attempted reaches and
the number of "hits" (defined as successful retrieval of a
pellet) were analyzed and recorded.
Grid walking was sensitive to deficits in descending
motor control. The grid walking apparatus consisted of
two plastic panels 1 m long and 25 cm wide (5 mm thick)
with holes drilled 1 cm apart along one long edge. The
panels were placed 2.5 cm apart and connected via several
metal bars (3 mm diameter) through the holes. The bars
were randomly placed 1, 2, or 3 cm apart. The apparatus
was suspended and oriented such that a narrow alley was
formed 1 m long with walls 25 cm high. The grid bars
formed the floor. The animals were individually placed at
one end of the apparatus and filmed from the side as they
walked across the bars to the opposite end. The number of
forelimb and hind limb placement errors over the final 50
cm was analyzed. An error was counted whenever a limb
missed a bar and extended through the horizontal plane
of the grid floor.
Forelimb strength was assessed using a Grip Strength
apparatus. Each mouse was held near a vertically oriented
apparatus such that it grabbed with the forelimbs a handle
that was fastened to a calibrated spring. Consistent and
increasing pressure was applied by pulling the mouse
downward until contact with the handle was broken. The
distance the mouse pulled the handle was recorded as the
strength score.
Rotarod was a test of sensorimotor coordination and was
sensitive to damage in the basal ganglia and the cerebel-
lum. All mice were trained to walk on a rotating drum (6
sessions over 2 days). During each test session the drum
was rotated at 10 rpm for 30 s followed by 5 rpm increases
every 10 s to a maximum of 45 rpm. The rotation speed at
which the mouse fell from the rotating drum was
recorded.
Statistics
A repeated measures analysis of variance (ANOVA) and
unpaired t-tests were performed on grouped data for each
mouse strain and for each of the behavioral tests.
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